- Home
- IMCR vs LILAK Comparison
IMCR vs LILAK Comparison
Compare IMCR & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | LILAK |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United Kingdom | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMCR | LILAK |
|---|---|---|
| Price | $36.21 | $7.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $67.00 | $8.20 |
| AVG Volume (30 Days) | 259.5K | ★ 816.9K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $379,590,000.00 | ★ $4,433,000,000.00 |
| Revenue This Year | $32.28 | $1.62 |
| Revenue Next Year | $10.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.11 | N/A |
| 52 Week Low | $23.15 | $4.23 |
| 52 Week High | $40.72 | $9.13 |
Technical Indicators
Market Signals| Indicator | IMCR | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 32.29 |
| Support Level | $35.41 | $7.52 |
| Resistance Level | $37.25 | $8.36 |
| Average True Range (ATR) | 1.58 | 0.31 |
| MACD | -0.18 | -0.12 |
| Stochastic Oscillator | 20.63 | 6.67 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.